SLC5A2 and type 2 diabetes mellitus: In patients with type 2 diabetes (T2D) and established cardiovascular diseases (CVD), treatment with empagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), has demonstrated reductions in the risks of major adverse cardiovascular events (MACE), mortality, hospitalization for heart failure (HHF), and kidney-related outcomes relative to placebo [1].